In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability

Author's Avatar
Nov 22, 2022

• Animal study shows effective protection of mitochondria from oxidative damage and reduced plaque vulnerability in advanced atherosclerosis following treatment with SOD2 mRNA nanoparticles based on Altamira's SemaPhore™ technology
• Data presented at American Heart Association Annual Scientific Sessions Chicago 2022, earlier this month